about
Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosusLongitudinal characterization of the brain proteomes for the tg2576 amyloid mouse model using shotgun based mass spectrometry.Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease.Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.Molecular biomarkers of neurodegeneration.Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.Synaptic proteins in CSF relate to Parkinson's disease stage markersA Season of American Football Is Not Associated with Changes in Plasma Tau.Expanding the cerebrospinal fluid endopeptidome.5-HT1B and other related serotonergic proteins are altered in APPswe mutation.Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.Astroglial activation and altered amyloid metabolism in human repetitive concussion.The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.Apolipoprotein E polymorphism in patients with cataract.Characterization of the effect of a novel γ-secretase modulator on Aβ: a clinically translatable model.Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients.Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels.Tau Diagnostics and Clinical Studies.Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury.Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia.Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease.Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials.A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.Cerebrospinal fluid markers of extracellular matrix remodeling, synaptic plasticity and neuroinflammation before and after cranial radiotherapy.Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers.Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury.Characterization of tau in cerebrospinal fluid using mass spectrometry.Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's disease.An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.Prevalence of preclinical Alzheimer disease: Comparison of current classification systems.Commentary: Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
P50
Q24793525-CF270D4B-08EF-42F0-85C8-5E03086B3989Q34438884-FB01711E-8835-4066-B8B8-57C92D6009D0Q36546521-520E0F63-AD6A-40C2-82BC-53601396BC45Q36830139-2CF3BF19-90F7-45B3-A676-43E3B19E8678Q36930444-4144F53B-E8A6-41F2-BD8C-DB1899750E2FQ36975405-F2FD69CF-7911-4AAC-AF5B-76CD8C86367DQ38154930-55F95232-7283-4488-9758-AF900FD35098Q38350755-5B6FC483-D591-4C05-85AC-71BE3618C8DCQ38666817-41CAA8A2-0B85-4D33-855D-4C485C7AD6BAQ38725576-62BF1A74-417D-4E05-B1CA-B9EF9FDF58A3Q38775378-CFC8A755-2576-4B8A-9E1B-ECE9DA665084Q38891023-7D416FC5-7A74-4BB5-B80D-296A1D384619Q39029436-BCE979CB-F136-4F50-8EF9-53CD428A0D3EQ40118493-FD8B682F-D39D-4605-B418-1634646B6290Q42292371-25B023A5-3EFB-4B69-A19A-E48F7F53E2F2Q42651492-53806AC7-3979-48B1-9A77-1E0C35E78041Q43007828-F5A4F145-026B-4B81-A799-A42BFA79F1B1Q43544368-B4E53A5D-C51B-4C98-A20F-A3F5DA8A8F90Q44574707-834F9B47-AD66-479C-A70A-9440CA71EB88Q44801299-C8D39862-E50A-4F89-8697-632FE623B037Q46181670-FF7EEF89-A0A8-4A09-8F8B-4CAF02F07473Q46529505-0AFEE380-762E-4BA1-89AE-148D77AF9C2EQ46863775-6F4DE2D6-727D-4ADF-A89B-6189318383B3Q47870437-25BB7037-C336-46A0-8703-62B33E52AC47Q47931927-65237553-C4B6-4C68-BE4F-6C77BADD8AABQ48016761-34DB23BE-F96C-471D-9850-C671892BCFAAQ48055903-84297703-D5EF-45D1-BEA8-7A8047D5368DQ48276674-CCBA3167-E7B1-4701-B769-79B2EF0092F1Q48444418-3E7F14EA-97C7-4EBF-B35F-8DD304D55166Q49686544-ED4E723B-97ED-4029-8C3A-095BA07015B6Q52583426-C9251A1F-4847-468C-8E24-C74B667554E6Q52870398-143FEA51-E8DC-455C-9CCE-05A7CAB3CACEQ53263063-20C0AE6F-2067-4485-9EF9-BF56E32715F3Q53293107-88DF1711-D42B-45E1-85C3-BD23716BB7C1Q53331697-B6727027-E385-487E-A1C2-4A6CE474079FQ53332329-7311EB31-D6CA-47CD-AE00-02EF4C7B0EF9Q53362115-E1149B98-AABD-4A4B-8A2D-676249851B78Q53389121-EC060EF3-A79A-4C74-916E-A59054957F35Q53513203-87DFDAE0-8531-46B5-BD0F-01736C7D21E0Q55375108-9ACB773E-B4AA-4483-8FF3-F195C74A09BD
P50
description
researcher ORCID ID = 0000-0002-1213-9953
@en
svensk forsker
@nb
name
K Höglund
@ast
K Höglund
@es
K Höglund
@nl
K Höglund
@sl
Kina Höglund
@da
Kina Höglund
@de
Kina Höglund
@en
Kina Höglund
@fr
Kina Höglund
@nb
Kina Höglund
@nn
type
label
K Höglund
@ast
K Höglund
@es
K Höglund
@nl
K Höglund
@sl
Kina Höglund
@da
Kina Höglund
@de
Kina Höglund
@en
Kina Höglund
@fr
Kina Höglund
@nb
Kina Höglund
@nn
prefLabel
K Höglund
@ast
K Höglund
@es
K Höglund
@nl
K Höglund
@sl
Kina Höglund
@da
Kina Höglund
@de
Kina Höglund
@en
Kina Höglund
@fr
Kina Höglund
@nb
Kina Höglund
@nn
P106
P1153
55883397700
P21
P27
P31
P496
0000-0002-1213-9953